Online inquiry

IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4230MR)

This product GTTS-WQ4230MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets Factor IX substitute gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000133.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2158
UniProt ID P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4230MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2581MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ15433MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TSR-033
GTTS-WQ1050MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-621
GTTS-WQ1559MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ7402MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ5645MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP870
GTTS-WQ1985MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ3232MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARGX-113
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW